
-
Assembly Biosciences NasdaqGS:ASMB Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5336 and ABI-1179, which are in Phase 1a/1b clinical studies for recurrent genital herpes; ABI-4334, a capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus that is in Phase 1b clinical study; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study. The company also develops ABI-7423, an oral broad-spectrum non-nucleoside polymerase inhibitor that targets transplant-related herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Location: Two Tower Place, South San Francisco, CA, 94080, United States | Website: https://www.assemblybio.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
20.45M
Cash
91.03M
Avg Qtr Burn
-14.05M
Short % of Float
0.57%
Insider Ownership
10.32%
Institutional Own.
41.72%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ABI-5366 Details Genital herpes (HSV), Sexually transmitted infections | Phase 1b Data readout | |
ABI-1179 Details Genital herpes (HSV), Sexually transmitted infections | Phase 1b Data readout | |
ABI-4334 Details Liver infection, Liver disease, Hepatitis B | Phase 1b Data readout | |
ABI-6250 Details Liver infection, Liver disease, Hepatitis Delta Virus, Hepatitis D | Phase 1a Data readout | |
ABI-H3733 Details Liver disease, Hepatitis B, Liver infection | Failed Discontinued | |
Vebicorvir (VBR, ABI-H0731) Details Liver infection, Chronic liver disease, Hepatitis B | Failed Discontinued | |
ABI-H2158 Details Liver infection, Liver disease, Hepatitis B | Failed Discontinued |